Abstract
A recent phase II study [1] has shown a high response rate of 50 % with Vinorelbine in metastatic breast cancer. It seemed logical to combine this new compound with the well tolerated and effective drugs Epirubicine and Methotrexate (respective response rate of 45% and 20%). A weekly (day 1 & 8) administration of Vinorelbine was performed as proposed in the phase II study; Epirubicine and Methotrexate were also infused at day 1 and 8 to decrease toxicity. In metastatic relapse, our aim was to increase complete response rate (CR); and in Neo-Adjuvant situation, aims were to obtain maximal tumor’s reduction to avoid modified radical mastectomy (MRM) and increase of clinical and pathological response rates.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fumoleau P et al (1990) Phase II trial with Navelbine in advanced breast cancer. Preliminary results. Asco 9 (1): Abst 76. French Epirubicin Study Group (1988) A prospective randomized phase III trial comparing combination chemotherapy with Cyclophosphamide, Fluorouracil, and either Doxorubicin or Epirubicin. J Clin Oncol 6: 679–688
Anderson EDC, Forrest APM, Hawkins RA, Anderson TJ, Leonard RCF, Chetty U (1991) Primary systemic therapy for operable breast cancer. Br J Cancer 63: 561–566
Mansi JL, Smith IE, Walsh G, et al (1989) Primary medical therapy for operable breast cancer. Eur J Cancer Oncol 25: 1623–1627
DeVita VT Jr (1990) Primary chemotherapy can avoid mastectomy, but there is more to it than that. J Natl Cancer Inst 82: 1522–1524
Jacquillat C, Weil M, Baillet F, et al (1990) Results of Neo-Adjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119–129
Jacquillat C, Baillet F, Auclerc G, et al (1984) Cancer du sein. Chimiothérapie précédant le traitement loco-régional avec extension des indications du traitement conservateur. Bull Cancer 7 (suppl 1): 5
Bonadonna G, Veronesi U, Brambilla C, et al (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of 3 centimeters or more. J Natl Cancer Inst 19: 539–545
Mauriac L (1990) Chimiothérapie première des cancers du sein opérables. Étude randomisée. Bull Cancer 77 (suppl 1): 47–53
Bélembaogo E, Feillel V, Chollet P, et al (1992) Neo-Adjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28: 896–900 (2)
Feldmann LD and al (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Research 46: 2578–2581
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag France
About this paper
Cite this paper
Van Praagh, I. et al. (1994). Efficacy of a chemotherapy regimen combining Vinorelbine, Epirubicine and Methotrexate (VEM) in locally advanced and metastatic breast cancer. In: Banzet, P., Holland, J.F., Khayat, D., Weil, M. (eds) Cancer Treatment An Update. Springer, Paris. https://doi.org/10.1007/978-2-8178-0765-2_24
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0765-2_24
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0767-6
Online ISBN: 978-2-8178-0765-2
eBook Packages: Springer Book Archive